TechCrunch · Marina Temkin ·

Colorado-based Enveda, which uses AI to discover new drugs in the natural world, raised a $311M Series E at a $2B valuation, double its valuation a year ago

Enveda, a biotech startup that uses AI to discover new drugs in the natural world, has raised a $311 million Series E at a $2 billion valuation.

AI Venture Capital

In this story Enveda

Colorado-based Enveda, which uses AI to discover new drugs in the natural world, raised a $311M Series E at a $2B valuation, double its valuation a year ago

Lead Source

TechCrunch — Colorado-based Enveda, which uses AI to discover new drugs in the natural world, raised a $311M Series E at a $2B valuation, double its valuation a year ago ↗

How this story grew

Coverage · 0 Discussion · 0

Sep 23Sep 25

More

Wall Street Journal: Wall Street Journal

Business Wire: Business Wire

Endpoints News: Endpoints News

Discussion

@upadhyayulahk @zavaindar @ky_lahucik @johncumbers @iconiqcapital @viswacolluru @enveda

Related stories

Reuters: Shanghai-based Anew Labs, a ByteDance spinoff using AI for drug discovery, raised $290M from HSG, IDG Capital, and others at a $1.5B valuation

Bloomberg: Forus, which uses AI to help patients get prescribed drugs more quickly by navigating steps like insurance coverage, raised a $150M Series C at a $3B valuation

Business Insider: Devoted Health, which uses AI to help coordinate medical care for those enrolled in Medicare Advantage, is raising new funding at a $25B valuation

Business Insider: OpenEvidence, an AI search engine for doctors, raised $250M at a $15B valuation, up from $12B in January; it could be open to selling itself

CNBC: Thyme Care, which focuses on filling cancer treatment gaps via a virtual navigation platform, raised a $125M Series E at a $2B+ valuation, up from $1B+ in 2025

Discuss with AI

ChatGPT ↗ Claude ↗

← Back to TechSnif